Robert W. Baird Cuts Immutep (NASDAQ:IMMP) Price Target to $6.00

Immutep (NASDAQ:IMMP) had its price objective reduced by Robert W. Baird from $7.00 to $6.00 in a report issued on Thursday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.

Separately, Capital One Financial initiated coverage on Immutep in a research note on Friday, May 17th. They set an overweight rating and a $10.00 price objective on the stock.

Immutep Stock Up 7.5 %

NASDAQ:IMMP opened at $2.01 on Thursday. The business’s 50 day moving average is $2.75 and its two-hundred day moving average is $2.51. Immutep has a 52 week low of $1.58 and a 52 week high of $3.34.

Institutional Investors Weigh In On Immutep

Institutional investors and hedge funds have recently bought and sold shares of the business. Meridian Wealth Management LLC grew its holdings in shares of Immutep by 3.6% during the fourth quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 11,250 shares during the last quarter. Virtu Financial LLC grew its stake in Immutep by 269.4% during the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after buying an additional 32,864 shares during the last quarter. BNP Paribas Financial Markets increased its position in Immutep by 15.4% in the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after buying an additional 4,700 shares during the period. Oracle Investment Management Inc. lifted its stake in Immutep by 9.4% in the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock valued at $1,316,000 after buying an additional 48,449 shares during the last quarter. Finally, PFG Investments LLC acquired a new position in shares of Immutep during the first quarter valued at $119,000. Institutional investors and hedge funds own 2.32% of the company’s stock.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.